Novo Nordisk's Paediatric Win Can't Mask the Questions Piling Up for September 21
Published on 09/07/2026 at 18:11 | Editorial boerse-global.de
The numbers from Copenhagen tell a story of clinical progress colliding with investor indifference. Novo Nordisk's phase 3 trial in children aged six to under twelve delivered exactly what the company would have hoped for — yet the market barely blinked.
Shares drifted 0.2 percent lower on the day to 39.99 euros, a telling response to data showing 40.4 percent of children treated with once-weekly semaglutide no longer met the definition of obesity after 68 weeks, against zero percent in the placebo arm. The safety profile matched earlier studies in adults and adolescents, with no new concerns flagged around growth or pubertal development.
The full dataset heads to the Obesity Society's ObesityWeek 2026 in Washington from November 14 to 17. But for investors, the more pressing date on the calendar arrives sooner.
While markets weigh clinical milestones, UK employers face a different kind of deadline pressure: staying compliant with workplace safety law. Many firms discover too late that missing risk assessments and outdated safety documents leave them exposed to significant fines. A free Health & Safety Toolkit provides ready-to-use templates and checklists aligned with UK regulations, helping you protect your team and your business. Download the free Health & Safety Toolkit
A Stock Trapped Between Two Analyst Camps
The equity's recent trajectory explains the muted reaction. Novo Nordisk trades roughly 27 percent below its January peak of 54.86 euros, having shed 9.3 percent since the start of the year. The 50-day moving average sits at 41.60 euros, the 200-day at 40.15 euros — the stock hovers just beneath both, directionless.
That sideways drift reflects a genuine split on the Street. Deutsche Bank cut the shares to Sell on August 27, trimming its price target to 265 Danish kroner and citing slowing growth into 2027, the late-stage failure of cardiovascular candidate Ziltivekimab, and patent expiry risk later in the decade. The bank reaffirmed that stance on September 2.
JPMorgan, by contrast, lifted its target from 250 to 275 Danish kroner on August 25 while holding at Neutral. The bank raised its 2026 revenue forecast by 5 percent, betting on more limited generic erosion for Ozempic and favourable US price adjustments.
Two credible institutions, two opposing conclusions. The bear case centres on the patent cliff and a depleted pipeline; the more constructive view holds that Novo Nordisk's pricing power across its blockbuster franchise remains intact for now.
Buybacks and a New Oral Front
Management, for its part, continues to signal confidence in the company's own worth. The ongoing buyback programme has now repurchased 32,034,179 B-shares since early February at an average price of 281.63 Danish kroner, totalling roughly 9.02 billion kroner as of September 4. The programme continues unchanged.
Operationally, the company is also extending its reach. Wegovy's oral tablet formulation launched in Germany just days ago — the first EU country to receive the oral semaglutide version — adding a new competitive angle against Eli Lilly's encroachment.
Just as Novo Nordisk is expanding its product reach, responsible employers are extending their own protection measures. Over 37,000 UK businesses already rely on a comprehensive free toolkit covering fire safety, PPE, first aid and more — everything needed to meet Health & Safety at Work Act obligations. Don't let compliance gaps become your liability. Get the free Health & Safety Toolkit
The London Test
None of this, however, has shifted the prevailing mood. Good news from the pipeline and steady capital returns have proved insufficient to reverse sentiment, which now hinges on the capital markets day scheduled for September 21 in London. Management has promised a comprehensive review of strategy, R&D pipeline, operations and performance, alongside new strategic ambitions.
That event will force clarity on precisely the questions dividing Deutsche Bank and JPMorgan: how quickly growth decelerates, what follows Ziltivekimab's failure, and how the company navigates the eventual loss of patent protection.
The paediatric data extends semaglutide's clinical franchise into uncharted territory, but the market's focus has shifted to the post-patent-cliff era. Until London provides answers, the shares look likely to remain locked in their narrow range — pharmaceutical progress notwithstanding.
